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Plasma Concentrations of Tranexamic Acid in
PostpartumWomen After
Oral Administration
Kopalasuntharam Muhunthan, MS, FRCOG, Sandrasegarampillai Balakumar, PhD,
Thiyahini S. Navaratnaraja, MD, Sundaralingam Premakrishna, MD,
and Sabaratnam Arulkumaran, PhD, FRCOG
OBJECTIVE: To evaluate the pharmacokinetics of tran-
examic acid after oral administration to postpartum
women.
METHODS: We conducted a single-center pharmacoki-
netic study at Teaching Hospital—Jaffna, Sri Lanka, on 12
healthy postpartum women who delivered vaginally.
After oral administration of 2 g of immediate-release
tranexamic acid 1 hour after delivery, pharmacoki-
netic parameters were measured on plasma samples
at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, and 12 hours.
Plasma tranexamic acid concentrations were deter-
mined by high-performance liquid chromatography. The
outcome measures were maximum observed plasma con-
centration, time to maximum plasma concentration, time
to reach effective plasma concentration, time period
effective serum concentration lasted, area under the curve
for drug concentration, and half-life of tranexamic acid.
RESULTS: The mean maximum observed plasma con-
centration was 10.06 micrograms/mL (range 8.56–12.22
micrograms/mL). The mean time to maximum plasma
concentration was 2.92 hours (range 2.5–3.5 hours).
Mean time taken to reach the effective plasma concen-
tration of 5 micrograms/mL and the mean time this con-
centration lasted were 0.87 hours and 6.73 hours,
respectively. Duration for which plasma tranexamic acid
concentration remained greater than 5 micrograms/mL
was 5.86 hours. Half-life was 1.65 hours. Area under the
curve for drug concentration was 49.16 micrograms.h/mL
(range 43.75–52.69 micrograms.h/mL).
CONCLUSION: Clinically effective plasma concentra-
tions of tranexamic acid in postpartum women may be
achieved within 1 hour of oral administration. Given the
promising pharmacokinetic properties, we recommend
additional studies with larger sample sizes to investigate
the potential of oral tranexamic acid for the treatment or
prophylaxis of postpartum hemorrhage.
(Obstet Gynecol 2020;00:1–4)
DOI: 10.1097/AOG.0000000000003750
Postpartum hemorrhage is one of the major com-plications in obstetrics and one of the leading
causes of maternal mortality worldwide, especially
in developing countries, where it accounts for 25%
of maternal deaths.1,2 The use of intravenous tran-
examic acid is recommended for the treatment of
postpartum hemorrhage if oxytocin and other utero-
tonics fail to stop bleeding or if it is thought that the
bleeding may be partly due to trauma.3 Intravenous
administration of tranexamic has been shown to be
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safe and effective in trauma and surgery, with no
apparent increase in vascular occlusive events.4 One
of the main barriers to rapid treatment with tranexa-
mic acid is the need for intravenous injection.5
The effective plasma concentration of tranexamic
acid that has been shown to cause significant inhibition
of systemic fibrinolysis in adults is 5–10 micrograms/
mL, with near maximal inhibition between 10 and 15
micrograms/mL.6 At a minimum concentration of 5
micrograms/mL, tranexamic acid has been shown to
increase the clot lysis time from 6 to 16 minutes.7
Our study was designed to investigate the phar-
macokinetics of oral tranexamic acid, a key step
toward considering its use, especially in low-
resourced countries, in an oral form for treatment or
prophylaxis of postpartum hemorrhage.
METHODS
The study was conducted at the University Obstetric
Unit, Teaching Hospital—Jaffna, after obtaining ethical
approval from Ethics Review Committee of the Fac-
ulty of Medicine, University of Jaffna. All procedures
performed were in accordance with good clinical
practice. The study cohort comprised 12 healthy post-
partum women aged 24–33 years who delivered sin-
gleton neonates vaginally.8 Recruited participants
were screened for contraindications to tranexamic
acid: past and current history of intravascular clotting,
hemorrhagic events, and procoagulant disorders.
None of the pregnancies had been complicated by
pregnancy-related medical disorders, and patients
with any preexisting comorbidities were not studied.
In addition to history and examination, electro-
cardiogram, liver function and renal function tests, full
blood count, and coagulation profile were performed
during the screening process. Written informed con-
sent was obtained from all participants.
All participants underwent routine active man-
agement of the third stage, with intravenous oxytocin
10 international units after delivery of the neonate,
delayed cord clamping, and controlled cord traction
to deliver the placenta. Blood loss was estimated by
weighing swabs and blood collected in a waterproof
drape on the labor ward.
An arterial line was established to obtain blood; 1
hour after delivery, all study participants were admin-
istered the same preparation of 2 g of immediate-
release tranexamic acid orally with 50 mL of water,
which corresponds in strength to 1 g of intravenous
tranexamic acid used to treat postpartum haemor-
rhage.5,9 The tranexamic acid preparation was supplied
by the Teaching Hospital—Jaffna, and all participants
were monitored for 24 hours for adverse effects.
Blood samples (1.8 mL) were collected in tubes
containing 0.2 mL of 3% sodium citrate at 0, 0.5, 1,
1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, and 12 hours after
administration of tranexamic acid and were immedi-
ately transported to the Biochemistry Laboratory,
Faculty of Medicine, University of Jaffna, where the
tranexamic acid assay was carried out. Within 1 hour
of collection, samples were centrifuged at 2,000g for
15 minutes at room temperature, and supernatants
were stored at 270°C until analysis.
During the analysis, samples were pretreated with
leucine dehydrogenase, and plasma tranexamic acid
concentration was determined by Shimadzu 10Avp
high-performance liquid chromatography using
ortho-phthalaldehyde derivatization as previously
described.10–13 Samples were analyzed on an Ultra
C18 5 micrometer 4.63150-mm column, and the tran-
examic acid derivative was detected fluorometrically
(Fluorometer Shimadzu RF-10Axl).
Samples for quality control were prepared with
a known quantity of standard tranexamic acid added
to analyte-free human plasma. Peak area for the high-
performance liquid chromatography assay was well
correlated for plasma concentration from 0 micro-
grams/mL to 15 micrograms/mL. The accuracy of the
assay method was between 97% and 99%. Descriptive
statistics were calculated from plasma concentration
compared with time data for single-dose pharmacoki-
netic parameters: maximum observed plasma concen-
tration and time to maximum plasma concentration
and their SDs using SPSS Statistics 23.
The linear trapezoidal method was used to
calculate the area under the curve for drug concen-
tration. Geometric means were calculated to estimate
the time pharmacologically effective drug concentra-
tions were reached and the duration for which the
pharmacologically effective concentrations lasted.
Elimination half-life for tranexamic acid was calcu-
lated as a parameter describing the linear terminal
slope of the log concentrations.
RESULTS
A total of 12 postpartum women participated in this
study. The mean age of the participants was 29 years,
with a range of 24–33 (Table 1). None of the partici-
pants developed any adverse effects during the obser-
vational period. Among the 12 participants, the mean
maximum observed plasma concentration was 10.06
micrograms/mL (range 8.56–12.22 micrograms/mL).
The maximum observed plasma concentration was
greater than 10 micrograms/mL in eight participants.
The mean time to maximum plasma concentration was
2.92 hours (range 2.5–3.5 hours) (Fig. 1 and Box 1).
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Because the effective plasma concentration of
tranexamic acid that has been shown to cause
significant inhibition of systemic fibrinolysis in adults
is 5–10 micrograms/mL, we have presented the time
course of plasma concentrations of tranexamic acid of
5 micrograms/mL and greater.6,7 After administra-
tion, the mean time taken to reach the plasma concen-
tration of 5 micrograms/mL was 0.87 hours and lasted
until 6.73 hours after the administration of the drug.
The duration for which plasma tranexamic acid con-
centration remained greater than 5 micrograms/mL
was 5.86 hours. Half-life was 1.65 hours. Area under
the curve for drug concentration was 49.16 micro-
grams.h/mL, with a range of 43.75–54.69 micro-
grams.h/mL between individual patients, with
percentage deviations of 92.5–111%.
DISCUSSION
We found that pharmacologically effective concen-
trations could be achieved within 1 hour of adminis-
tration of 2 g oral tranexamic acid in postpartum
women. Being able to achieve pharmacologically
effective concentrations of 5 micrograms/mL and
greater in postpartum women with the above oral
dose within 1 hour was encouraging, because the
World Health Organization guideline recommends
the use of tranexamic acid within a 3-hour of window
from birth.4 Though not comparable with intravenous
administration of tranexamic acid, where effective
plasma concentration is reached immediately, orally
administered tranexamic acid shows potential to be
effective in the management of postpartum
hemorrhage.
This effective concentration is supported by
a recent meta-analysis that concluded that the plasma
tranexamic acid concentrations in adults from 10
micrograms/mL to 15 micrograms/mL provide near
maximal inhibition of fibrinolysis, and concentrations
from 5 micrograms/mL to 10 micrograms/mL provide
Table 1. Demographics of the Participants
Variable Value
Age (y) 28 (24–33)
Parity 2 (1–2)
Weight (kg) (measured at the onset of
labor)
64 (59–72)
Height (cm) 158 (150–165)
BMI (kg/m2) 25.8 (24.3–28.9)
Estimated blood loss (mL) 230 (170–300)
Birth weight (g) 3,120 (2,730–3,770)
BMI, body mass index.
Data are median (range).
Fig. 1. Mean plasma concentration
of tranexamic acid in micrograms/
mL vs time curve after a single dose
of 2 g of oral tranexamic acid in
postpartum women. Error bars
represent the range.
Muhunthan. Oral Tranexamic Acid in
Postpartum Women. Obstet Gynecol
2020.
Box 1. Pharmacokinetic Values
Cmax: 10.06 micrograms/mL
Range: 8.56–12.22 micrograms/mL
Tmax: 2.92 h
Range: 2.5–3.5 h
AUC0–12: 49.16 micrograms.h/mL
Range: 43.75–52.69 micrograms.h/mL
% deviation from the mean: 92.5–111%
T1/2: 1.65 h
Mean time course of concentration 5 micrograms/mL
or greater (h)
Initial: 0.87
Final: 6.73
Duration: 5.86
Cmax, maximum observed plasma concentration; Tmax, time to
maximum plasma concentration; AUC0–12, area under the
curve for drug concentration; T1/2, half-life.
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significant inhibition of systemic fibrinolysis in
adults.6,7 Further, this effective concentration lasted
for almost 6 hours.
The maximum observed plasma concentration of
10.0660.79 micrograms/mL is lower than the previ-
ously reported plasma concentrations of 13–14.8 mi-
crograms/mL after a single oral-dose regimen in
nonpregnant patients.9,14 This may be a result of the
higher volume of distribution in postpartum women.
The elimination half-life of 1.65 hours is shorter than
previously reported values of 2–3 hours for nonpreg-
nant patients.15 Because 95% of tranexamic acid is
excreted by the kidneys, an increase of glomerular
filtration rate by 50% during pregnancy may explain
this observation.9,16 The main limitations of our study
were its small sample size and relatively low body
mass index of the study participants.
Given the promising pharmacokinetic properties,
we recommend additional studies with larger sample
sizes to investigate the potential of oral tranexamic
acid for the treatment or prophylaxis of postpartum
hemorrhage.
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